Catalent vs Minaris Advanced Therapies: CDMO Comparison
Side-by-side comparison of Catalent and Minaris Advanced Therapies on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Catalent →
76.5
Somerset, NJ (now Novo Holdings)
Signal Score
76/100
Quality (FDA + GMP)
79/100
FDA inspections
10
— NAI / VAI / OAI
3 / 6 / 1
FDA warning letters
2
EMA GMP certificates (active)
14
MHRA GMP certificates (compliant)
16
Clinical programs (matched)
0
Capacity
—
Modalities
AAV, CAR-T, Lentiviral, Plasmid DNA
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score
84/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
2
MHRA GMP certificates (compliant)
4
Clinical programs (matched)
0
Capacity
Limited
Modalities
CAR-T, Cell Therapy
Evaluating Catalent and Minaris Advanced Therapies for a program?
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.